PVCT Financial Facts

Net loss applicable to common shareholders: -8.86M
Gain on change in fair value of warrant liability: 336.65K
See Full Income Statement

Accrued consulting expense: 192K
Deficit accumulated during the development stage: -200.22M
See Full Balance Sheet

Provectus Biopharma (PVCT) Earnings

  |   Expand Research on PVCT
Next EPS Date N/A EPS Growth Rate N/A
Average EPS % Beat Rate N/A Revenue Growth Rate N/A
Average % Move 1-Wk after EPS N/A Normal Earnings Time After Close
Date  Qtr EPS Cons. Surprise Revs Cons. Gd. 1-Week % 1-Day % Details
8/14/25 Q225 N/AN/A N/A N/AN/A N/A N/A N/A
11/18/24 Q424 N/AN/A N/A N/AN/A N/A N/A N/A
11/14/24 Q324 $0.00N/A N/A $110KN/A N/A Details
11/8/24 Q324 N/AN/A N/A N/AN/A N/A N/A N/A
8/26/24 Q224 N/AN/A N/A N/AN/A N/A N/A N/A
8/19/24 Q224 N/AN/A N/A N/AN/A N/A N/A N/A
8/12/24 Q224 N/AN/A N/A N/AN/A N/A N/A N/A
8/7/24 Q224 N/AN/A N/A N/AN/A N/A N/A N/A